全文获取类型
收费全文 | 261篇 |
免费 | 18篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 8篇 |
妇产科学 | 7篇 |
基础医学 | 38篇 |
口腔科学 | 12篇 |
临床医学 | 31篇 |
内科学 | 49篇 |
皮肤病学 | 5篇 |
神经病学 | 29篇 |
特种医学 | 7篇 |
外科学 | 23篇 |
综合类 | 1篇 |
预防医学 | 19篇 |
眼科学 | 4篇 |
药学 | 26篇 |
中国医学 | 3篇 |
肿瘤学 | 14篇 |
出版年
2024年 | 1篇 |
2023年 | 10篇 |
2022年 | 11篇 |
2021年 | 23篇 |
2020年 | 19篇 |
2019年 | 30篇 |
2018年 | 27篇 |
2017年 | 13篇 |
2016年 | 18篇 |
2015年 | 14篇 |
2014年 | 20篇 |
2013年 | 17篇 |
2012年 | 25篇 |
2011年 | 24篇 |
2010年 | 9篇 |
2009年 | 2篇 |
2008年 | 5篇 |
2007年 | 3篇 |
2006年 | 3篇 |
2004年 | 1篇 |
2003年 | 2篇 |
2002年 | 1篇 |
1999年 | 1篇 |
1997年 | 1篇 |
排序方式: 共有280条查询结果,搜索用时 15 毫秒
1.
2.
Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development
Seyed Hossein Kiaie Mohammad Javad Sanaei Masoud Heshmati Zahra Asadzadeh Iman Azimi Saleh Hadidi Reza Jafari Behzad Baradaran 《药学学报(英文版)》2021,11(5):1083-1097
Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa.KEY WORDS: Immune checkpoint, Pancreatic cancer, Tumor microenvironment, Immunotherapy, Clinical development 相似文献
3.
4.
Shirvani Hossein Rostamkhani Fatemeh Arabzadeh Ehsan Mohammadi Faezeh Mohammadi Fatemeh 《Sport Sciences for Health》2021,17(4):849-854
Sport Sciences for Health - The widespread prevalence and mortality of coronavirus diseases-2019 (COVID-19) lead many researchers to study the SARS-CoV-s2 infection to find a treatment for this... 相似文献
5.
Vahid Farnia Jalal Shakeri Faezeh Tatari Toraj Ahmadi Juibari Katayoun Yazdchi Hafez Bajoghli 《The American journal of drug and alcohol abuse》2014,40(1):10-15
Background: Lifetime prevalence of amphetamine-induced psychotic disorder is reported as being up to 23% for methamphetamine (MA) abusers. Approximately 25% of those with a baseline DSM-IV diagnosis of substance-induced psychosis are diagnosed with primary psychosis at one-year follow-up. Evidence on the treatment of amphetamine psychosis is very limited. Objectives: To investigate the efficacy of risperidone versus aripiprazole in treatment of amphetamine-induced psychotic symptoms. Methods: In a double-blind study, 45 participants were randomly allocated to either aripiprazole 15?mg or risperidone 4?mg daily over a six-week trial. Positive and negative symptoms of psychosis were assessed using the Scale for Assessment of Negative Symptoms (SANS) and the Scale for Assessment of Positive Symptoms (SAPS) at baseline and completion of the trial. Results: SANS and SAPS scores decreased significantly in both groups. Mean SAPS score reduction in risperidone and aripiprazole group was 16.20 and 10.80, respectively, after trial course (p?0.001). Mean SANS score reduction in risperidone and aripiprazole group was 9.35 and 11.25, respectively (p?=?0.08). Conclusions: Both aripiprazole and risperidone were effective for patients diagnosed with amphetamine-induced psychotic disorder. However, risperidone had the greater effect on positive psychotic symptoms while patients with negative symptoms may respond better to aripiprazole. There is a case for further studies evaluating the efficacy of atypical antipsychotics in this disorder. 相似文献
6.
7.
8.
Nahid Dehghan-Nayeri Zohreh Khakbazan Faezeh Ghafoori 《Disability and health journal》2018,11(2):274-280
Background
Multiple sclerosis (MS) is a debilitating and life-long disease that affects the sexual life of people. However, in Iran little attention has been paid to the sexual life of women with MS.Objective
The aim of this study was to understand the sexual life and experiences of Iranian women with multiple sclerosis.Methods
A qualitative study was designed, and face-to-face semi-structured interviews were conducted with twenty-five women with MS. The interviews were tape-recorded and transcribed verbatim. Data were analyzed using a content analysis approach and through MAXQDA.10 software.Results
The main themes identified during the analysis were: (1) limited sexual activity, (2) sex life behind the mask, and (3) lack of sexual support during the rehabilitation process. In fact, the participants in this study expressed that their sexual activity was negatively affected by MS. They were trying to hide their sexual problems, and present themselves to their husbands differently from what they are, which can be considered as sex life behind the mask. Furthermore, Iranian women with MS received little sexual support from the rehabilitation team.Conclusions
Hiding sexual problems from husbands is thought to be a common practice and behavior among Iranian women with MS. Understanding this insight and its consequences can assist the rehabilitation team in helping and solving sexual problems of women with MS. Moreover, sexual awareness and education should be extended, especially among the husbands of women with MS. 相似文献9.
Seyed Mostafa Monzavi Aida Alirezaei Zhaleh Shariati-Sarabi Jalil Tavakol Afshari Mahmoud Mahmoudi Banafsheh Dormanesh Faezeh Jahandoost Ali Reza Khoshdel Ali Etemad Rezaie 《Inflammopharmacology》2018,26(5):1175-1182
Background
Hydroxychloroquine (HCQ) is a widely prescribed medication to patients with systemic lupus erythematosus (SLE), with potential anti-inflammatory effects. This study was performed to investigate the efficacy of HCQ therapy by serial assessment of disease activity and serum levels of proinflammatory cytokines in SLE patients.Methods
In this prospective cohort study, 41 newly diagnosed SLE patients receiving 400 mg HCQ per day were included. Patients requiring statins and immunosuppressive drugs except prednisolone at doses lower than 10 mg/day were excluded. Outcome measures were assessed before commencement of HCQ therapy (baseline visit) as well as in two follow-up visits (1 and 2 months after beginning the HCQ therapy). Serum samples of 41 age-matched healthy donors were used as controls.Results
Median levels of IL-1β (p?<?0.001), IL-6 (p?=?0.001), and TNF-α (p?<?0.001) were significantly higher, whereas, median CH50 level was significantly lower (p?<?0.001) in SLE patients compared with controls. Two-month treatment with HCQ resulted in significant decrease in SLEDAI-2K (p?<?0.001), anti-dsDNA (p?<?0.001), IL-1β (p?=?0.003), IL-6 (p?<?0.001) and TNF-α (p?<?0.001) and a significant increase in CH50 levels (p?=?0.012). The reductions in SLEDAI-2K and serum levels of IL-1β and TNF-α were significantly greater in the first month compared with the reductions in the second month.Conclusion
HCQ therapy is effective on clinical improvement of SLE patients through interfering with inflammatory signaling pathways, reducing anti-DNA autoantibodies and normalizing the complement activity.10.